Troboembolia de pulmón

  1. Jiménez Castro, David
  2. Kopecna, D.
  3. de Miguel Díez, Javier
  4. Sueiro Bendito, Antonio
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2014

Título del ejemplar: Enfermedades respiratorias (VI): Enfermedades vasculares pulmonares y pleurales

Serie: 11

Número: 68

Páginas: 4051-4058

Tipo: Artículo

DOI: 10.1016/S0304-5412(14)70882-0 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

La tromboembolia de pulmón (TEP) es la tercera causa de muerte cardiovascular tras el infarto agudo de miocardio y el ictus, y supone la primera causa de muerte prevenible en el hospital. Su diagnóstico requiere la combinación de la probabilidad clínica, los resultados del dímero D y las pruebas de imagen. La mayoría de los pacientes responden al tratamiento anticoagulante y la fibrinolisis se reserva para una minoría que comienza con situación de inestabilidad hemodinámica. La duración del tratamiento nunca debe ser inferior a los 3 meses, y se debe valorar su prolongación en aquellos pacientes con TEP idiopática o con un factor de riesgo trombótico persistente.

Referencias bibliográficas

  • Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta analysis. Circulation. 2008;117:93-102.
  • Agnelli G, Büller HR, Cohen A, Curto M, Gallus AS, Johnson M. Oral apixabán for the treatment of acute venous thromboembolism. N Engl J Med 2013;29;369(9):799-808.
  • Agnelli G, Büller HR, Cohen A, Curto M, Gallus AS, Johnson M. Apixabán for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699-708.
  • Akl EA, Kahale L, Neumann I, Barba M, Sperati F, Terrenato Il. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2014;6:CD006649.
  • Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005;172:1041-6.
  • Aujesky D, Roy PM, Verschuren F, Righini M, Osterwalder J, Egloff M. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non inferiority trial. Lancet. 2011;378:41-8.
  • Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366:1959-67.
  • Becattini C, Agnelli G, Vedovati MC, Pruszczyk P, Casazza F, Grifoni S. Multidetector computed tomography for acute pulmonary embolism: diagnosis and risk stratification in a single test. Eur Heart J. 2011;32:1657-63.
  • Binder L, Pieske B, Olschewski M, Geibel A, Klostermann B, Reiner C. N-terminal probrain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation. 2005;112:1573-9.
  • Blanco-Molina A, Rota LL, Di Micco P, Brenner B, Trujillo-Santos J, Ruiz-Gamietea A. Venous thromboembolism during pregnancy, postpartum or during contraceptive use. Thromb Haemost. 2010;103:306-11.
  • Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ. 2011;342:d3036.
  • Bova C, Sánchez O, Prandoni P, Lankeit M, Konstantinides S, Vanni S. Identification of intermediate risk patients with acute symptomatic pulmonary embolism: analysis of individual participants’ data from six studies. Eur Respir J. En prensa 2014.
  • Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P. Low dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367:1979-87.
  • Carrier M, Righini M, Djurabi RK, Huisman MV, Perrier A, Wells PSl. VIDAS D-dimer in combination with clinical pretest probability to rule out pulmonary embolism. A systematic review of management outcome studies. Thromb Haemost. 2009;101:886-92.
  • Carrier M, Rodger MA, Wells PS, Righini M, LE Gal G. Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost. 2011;9:1119-25.
  • Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep vein thrombosis. N Engl J Med. 1998;338:409-15.
  • Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121:1630-6.
  • Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ, III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160:809-15.
  • Henriksson P, Westerlund E, Wallén H, Brandt L, Hovatta O, Ekbom A. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ. 2013;346:e8632.
  • Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med. 2006;166:729-36.
  • Hokusai-VTE investigators, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH. Edoxabán versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406-15.
  • Jaff MR, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, Jenkins S. Management of Massive and Submassive Pulmonary Em-bolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement From the American Heart Association. Circulation. 2011; 23:1788-830.
  • Jiménez D, Aujesky D, Moores L, Gómez V, Martí D, Briongos S. Combinations of prognostic tools for identification of high risk normotensive patients with acute symptomatic pulmonary embolism. Thorax. 2011;66:75-81.
  • Jiménez D, Aujesky D, Díaz G, Monreal M, Otero R, Martí D. Prognostic significance of concomitant deep vein thrombosis in patients presenting with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med. 2010;181:983-91.
  • Jiménez D, Aujesky D, Yusen RD. Risk stratification of normotensive patients with acute pulmonary embolism. Br J Haematol. 2010;151:415-24.
  • Jiménez D, Uresandi F, Otero R, Lobo JL, Monreal M, Martí D. Troponin based risk stratification of patients with nonmassive pulmonary embolism: systematic review and metaanalysis. Chest. 2009;136:974-82.
  • Jiménez D, Aujesky D, Moores L, Gómez V, Lobo JL, Uresandi F,. Simplification of the Pulmonary Embolism Severity Index for prognosticating patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010;170:1383-9.
  • Klok FA, Mos IC, Huisman MV. Brain type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med. 2008;178:425-30.
  • Leung AN, Bull TM, Jaeschke R, Lockwood CJ, Boiselle PM, Hurwitz LM. American Thoracic Society documents: an official American Thoracic Society/Society of Thoracic Radiology Clinical Practice Guideline. Evaluation of suspected pulmonary embolism in pregnancy. Radiology. 2012;262:635-46.
  • Lobo JL, Zorrilla V, Aizpuru F, Uresandi F, García-Bragado F, Conget F. Clinical syndromes and clinical outcome in patients with pulmonary embolism: findings from the RIETE registry. Chest. 2006;130:1817-22.
  • Meneveau N, Séronde MF, Blonde MC, Legalery P, Didier-Petit K, Briand F. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest. 2006;129:1043-50.
  • Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J. Fibrinolysis for patients with acute intermediate risk pulmonary embolism. N Engl J Med. 2014;370:1402-11.
  • Mos IC, Klok FA, Kroft LJ, De Roos A, Dekkers OM, Huisman MV. Safety of ruling out acute pulmonary embolism by normal computed tomography in patients with an indication for computed tomography: systematic review and meta-analysis. J Thromb Haemost. 2009;7:1491-8.
  • Muriel A, Jiménez D, Aujesky D, Bertoletti L, Doecousus H, Laporte S, . Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Col Cardiol. 2014;63:1675-83.
  • Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355:1780-9.
  • Pomero F, Ageno W, Serraino C, Borretta V, Gianni M, Fenoglio L. The role of inherited thrombophilia in patients with isolated pulmonary embolism: a systematic review and a meta-analysis of the literature. Thromb Res. 2014;134:84-9.
  • Quinlan DJ, MCQuillan A, Eikelboom JW. Low molecular weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism. A meta-analysis of randomized, controlled trials. Ann Intern Med. 2004;140:175-83.
  • Rodger MA, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179: 417-26.
  • Roy PM, Meyer G, Vielle B, Le Gall C, Verschuren F, Carpentier F. Appropriateness of diagnostic management and outcomes of suspected pulmonary embolism. Ann Intern Med. 2006;144:157-64.
  • Sanchez O, Trinquart L, Colombet I, Durieux P, Huisman MV, Chatellier G. Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J. 2008;29:1569-77.
  • Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P. Treatment of acute venous thromboembolism with dabigatrán or warfarin and pooled analysis. Circulation. 2014;129:764-72.
  • Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D. Extended use of dabigatrán, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368:709-18.
  • Tosetto A, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism. A proposed prediction score (DASH). J Thromb Haemost. 2012;10:1019-25.
  • Trujillo-Santos J, Schellong S, Falga C, Zorrilla V, Gallego P, Barrón M. Low molecular weight or unfractionated heparin in venous thromboembolism: the influence of renal function. Am J Med. 2013;126:425-34.
  • Uresandi F, Monreal M, García-Bragado F, Domenech P, Lecumberri R, Escribano P. National consensus on the diagnosis, risk stratification and treatment of patients with pulmonary embolism. Arch Bronconeumol. 2013;49:534-47.
Fuente de los datos: Dialnet